Solventum Corp. (SOLV)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $15.14B
Last updated: Nov 17, 2026 at 11:05 AM ET
Solventum Corp. (SOLV) P/E Ratio & Valuation Multiples
Solventum (SOLV) trades at 12.6x trailing earnings and 1.9x sales. Its forward P/E is 12.9x. The median P/E across 11 similar companies is 21.2x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 2.3% lower over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 12.6x |
| Forward P/E | 12.9x |
| Price to sales | 1.9x |
| Price to book | 3.2x |
|---|---|
| EV/EBITDA | 21.1x |
| PEG | 1.2 |
As of Nov 17, 2026
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About SOLV
What is SOLV's forward P/E ratio?
Solventum has a forward P/E ratio of 12.9x.
Is SOLV stock overvalued?
GNG's valuation label for SOLV is Fairly valued. Its P/E of 12.6x compares with a median of 21.2x across 11 similar companies.
What is SOLV's price to sales ratio?
Solventum has a price to sales ratio of 1.9x.
What is SOLV's PEG ratio?
Solventum has a PEG ratio of 1.2.
SOLV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors